186 related articles for article (PubMed ID: 24151854)
1. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.
Shetty S; Ahmed AR
Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854
[TBL] [Abstract][Full Text] [Related]
2. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
3. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.
Li Y; Foshee JB; Sontheimer RD
J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477
[TBL] [Abstract][Full Text] [Related]
4. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
5. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for autoimmune blistering diseases: recent studies, new insights.
Lunardon L; Payne AS
G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of rituximab in autoimmune blistering diseases.
Ahmed AR; Shetty S
Am J Clin Dermatol; 2015 Jun; 16(3):167-77. PubMed ID: 25791770
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in dermatology.
España A; Ornilla E; Panizo C
Actas Dermosifiliogr; 2013 Jun; 104(5):380-92. PubMed ID: 23665436
[TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy for autoimmune haematological diseases.
Barcellini W; Zanella A
Eur J Intern Med; 2011 Jun; 22(3):220-9. PubMed ID: 21570637
[TBL] [Abstract][Full Text] [Related]
13. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
Feldman RJ; Ahmed AR
Expert Rev Clin Immunol; 2011 Jul; 7(4):529-41. PubMed ID: 21790294
[TBL] [Abstract][Full Text] [Related]
14. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
[TBL] [Abstract][Full Text] [Related]
17. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
18. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
Cravedi P
G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
[TBL] [Abstract][Full Text] [Related]
19. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
Ahmed AR
Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.
Tsai MJ; Chou CW; Lin FC; Chang SC
Lupus; 2012 Jul; 21(8):914-8. PubMed ID: 22287506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]